Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Run Lin

Showing results (451-460 of 457) with videos related to

Pageof 46
Sort By:
You have reached the last page of results.This site can display upto 457 results.
Zhonghua Xin Xue Guan Bing Za Zhi|May 11, 2010
[Clinical characteristics and outcome comparison between young (< or = 45 years) female and male patients with coronary artery disease undergoing percutaneous coronary intervention]Jing-han Huang, Shu-bin Qiao, Bo Xu, et al.
Nature Cancer|March 5, 2026
CRTAM inhibition mitigates toxicity of immune checkpoint inhibitors without antitumor efficacy trade-offSi-Cong Ma, Zi-Xuan Rong, Zi-Peng Xu, et al.
Biomedical and Environmental Sciences : BES|July 8, 2026
Joint Impact of Triglyceride-glucose Index and Free Fatty Acid Levels on Cardiovascular Outcomes in Overweight or Obese Patients with Coronary Artery Disease - A Large Multicenter Prospective StudyQue Yun Sun, Cheng Cui, Wei Ting Cai, et al.
International Journal of Cardiology|April 17, 2007
Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "Real World"--clinical and angiographic results from the China CYPHER Select registryRun-Lin Gao, Bo Xu, Shu-Zheng Lu, et al.
Zhonghua Yi Xue Za Zhi|December 18, 2010
[Comparison of outcomes after transradial intervention in patients of different age groups]Sheng-wen Liu, Shu-bin Qiao, Bo Xu, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|May 26, 2011
[The in-hospital outcome and predictors of major adverse cardiac events after transradial intervention in patients with coronary artery disease]Sheng-Wen Liu, Shu-Bin Qiao, Bo Xu, et al.
Regenerative Medicine|December 13, 2019
Transplantation efficacy of autologous bone marrow mesenchymal stem cells combined with atorvastatin for acute myocardial infarction (TEAM-AMI): rationale and design of a randomized, double-blind, placebo-controlled, multi-center, Phase II TEAM-AMI trialJun-Yan Xu, Hai-Yan Qian, Pei-Sen Huang, et al.
Pageof 46

Showing results (451-460 of 457) with videos related to

Sort By:
Pageof 46
You have reached the last page of results.This site can display upto 457 results.
Zhonghua Xin Xue Guan Bing Za Zhi|May 11, 2010
[Clinical characteristics and outcome comparison between young (< or = 45 years) female and male patients with coronary artery disease undergoing percutaneous coronary intervention]Jing-han Huang, Shu-bin Qiao, Bo Xu, et al.
Nature Cancer|March 5, 2026
CRTAM inhibition mitigates toxicity of immune checkpoint inhibitors without antitumor efficacy trade-offSi-Cong Ma, Zi-Xuan Rong, Zi-Peng Xu, et al.
Biomedical and Environmental Sciences : BES|July 8, 2026
Joint Impact of Triglyceride-glucose Index and Free Fatty Acid Levels on Cardiovascular Outcomes in Overweight or Obese Patients with Coronary Artery Disease - A Large Multicenter Prospective StudyQue Yun Sun, Cheng Cui, Wei Ting Cai, et al.
International Journal of Cardiology|April 17, 2007
Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "Real World"--clinical and angiographic results from the China CYPHER Select registryRun-Lin Gao, Bo Xu, Shu-Zheng Lu, et al.
Zhonghua Yi Xue Za Zhi|December 18, 2010
[Comparison of outcomes after transradial intervention in patients of different age groups]Sheng-wen Liu, Shu-bin Qiao, Bo Xu, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|May 26, 2011
[The in-hospital outcome and predictors of major adverse cardiac events after transradial intervention in patients with coronary artery disease]Sheng-Wen Liu, Shu-Bin Qiao, Bo Xu, et al.
Regenerative Medicine|December 13, 2019
Transplantation efficacy of autologous bone marrow mesenchymal stem cells combined with atorvastatin for acute myocardial infarction (TEAM-AMI): rationale and design of a randomized, double-blind, placebo-controlled, multi-center, Phase II TEAM-AMI trialJun-Yan Xu, Hai-Yan Qian, Pei-Sen Huang, et al.
Pageof 46